Baidu
map

肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

2022 循证临床实践指南：乳腺外佩吉特病

2022-01-20 国外肿瘤科相关专家小组（统称） JAMA Oncol

妇瘤乳腺肿瘤乳腺外佩吉特病

乳腺外佩吉特病(EMPD)是一种罕见的复发性恶性肿瘤，具有转移潜能，见于老年人生殖器、肛周和腋窝皮肤。本文主要针对EMPD的管理提供指导建议。

中文标题：

2022 循证临床实践指南：乳腺外佩吉特病

英文标题：

Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease

发布机构：

国外肿瘤科相关专家小组（统称）

发布日期：

2022-01-20

简要介绍：

乳腺外佩吉特病(EMPD)是一种罕见的复发性恶性肿瘤，具有转移潜能，见于老年人生殖器、肛周和腋窝皮肤。本文主要针对EMPD的管理提供指导建议。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2022 循证临床实践指南：乳腺外佩吉特病.pdf)] GetToolGuiderByIdResponse(projectId=1, id=11f3b1c0023311a4, title=2022 循证临床实践指南：乳腺外佩吉特病, enTitle=Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease, guiderFrom=JAMA Oncol, authorId=0, author=, summary=乳腺外佩吉特病(EMPD)是一种罕见的复发性恶性肿瘤，具有转移潜能，见于老年人生殖器、肛周和腋窝皮肤。本文主要针对EMPD的管理提供指导建议。, cover=https://img.medsci.cn/2022121/1642734508228_1608702.png, journalId=0, articlesId=null, associationId=887, associationName=国外肿瘤科相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Thu Jan 20 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">乳腺外佩吉特病(EMPD)是一种罕见的复发性恶性肿瘤，具有转移潜能，见于老年人生殖器、肛周和腋窝皮肤。本文主要针对EMPD的管理提供指导建议。</span></p>, tagList=[TagDto(tagId=117297, tagName=妇瘤乳腺肿瘤), TagDto(tagId=121927, tagName=乳腺外佩吉特病)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4468, appHits=45, showAppHits=0, pcHits=744, showPcHits=4423, likes=0, shares=13, comments=3, approvalStatus=1, publishedTime=Fri Jan 21 11:04:18 CST 2022, publishedTimeString=2022-01-20, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=dajiong, createdTime=Fri Jan 21 11:10:03 CST 2022, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Fri Jan 05 19:14:52 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 循证临床实践指南：乳腺外佩吉特病.pdf)])
2022 循证临床实践指南：乳腺外佩吉特病.pdf
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2137763, encodeId=d00f213e7636e, content=怎么看啊, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ae8691060, createdName=糖猫, createdTime=Thu May 18 23:30:11 CST 2023, time=2023-05-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2097402, encodeId=a2a2209e4021e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=53ec5542142, createdName=zhixu666, createdTime=Sun Oct 30 00:02:50 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187073, encodeId=746b118e07316, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Jan 22 07:24:04 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
    2023-05-18 糖猫 来自河北省

    怎么看啊

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2137763, encodeId=d00f213e7636e, content=怎么看啊, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ae8691060, createdName=糖猫, createdTime=Thu May 18 23:30:11 CST 2023, time=2023-05-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2097402, encodeId=a2a2209e4021e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=53ec5542142, createdName=zhixu666, createdTime=Sun Oct 30 00:02:50 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187073, encodeId=746b118e07316, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Jan 22 07:24:04 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
    2022-10-30 zhixu666

    学习学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2137763, encodeId=d00f213e7636e, content=怎么看啊, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ae8691060, createdName=糖猫, createdTime=Thu May 18 23:30:11 CST 2023, time=2023-05-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2097402, encodeId=a2a2209e4021e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=53ec5542142, createdName=zhixu666, createdTime=Sun Oct 30 00:02:50 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187073, encodeId=746b118e07316, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Jan 22 07:24:04 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
    2022-01-22 微探

    学习学习

    0

相关指南

中国家族遗传性肿瘤临床诊疗专家共识（2021年版）(1)——家族遗传性乳腺癌

中国抗癌协会家族遗传性肿瘤专业委员会 · 2021-12-15

2022 ESTRO共识建议：早期乳腺癌体外放疗的病患选择、剂量和分割

欧洲放射肿瘤学学会(ESTRO,European Society of Radiotherapy & Oncology) · 2021-12-30

河南省肿瘤诊疗质量控制中心乳腺癌术后放射治疗专家共识

河南省肿瘤诊疗质量控制中心乳腺癌专家委员会 · 2021-11-28

河南省肿瘤诊疗质量控制中心晚期乳腺癌专家共识

河南省肿瘤诊疗质量控制中心乳腺癌专家委员会 · 2021-11-28

河南省肿瘤诊疗质量控制中心乳腺癌规范化病理诊断专家共识

河南省肿瘤诊疗质量控制中心乳腺癌专家委员会 · 2021-11-28

河南省肿瘤诊疗质量控制中心早期乳腺癌手术治疗专家共识

河南省肿瘤诊疗质量控制中心乳腺癌专家委员会 · 2021-11-28

Baidu
map
Baidu
map
Baidu
map